Abstract
The stage of disease at presentation is the most important predictor of outcome for colon cancer patients. Stage I (T1-2N0M0) disease carries an excellent prognosis of up to 95% 5-year survival rate after resection, and surgical treatment alone is considered sufficient; adjuvant treatment is not indicated.1 Patients with stage II disease (T3-4N0M0) also have excellent 5-year survival, averaging 70–80%, but a subset of high-risk patients have poorer prognosis.1 As such, it has been suggested that some stage II patients may benefit from adjuvant therapy, but the role of treatment in this patient population remains controversial. In contrast, adjuvant treatment repeatedly has been shown to improve survival for stage III (TanyN1-2M0) disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Parkin DM et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.
Jemal A et al. Cancer statistics, 2002. CA Cancer J Clin. 2002;52(1):23–47.
NCCNetwork. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2003;1:40–53.
Wolmark N et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst. 1988;80(1):30–6.
Laurie JA et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol. 1989;7(10):1447–56.
Moertel CG et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322(6):352–8.
Conference NC. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444–50.
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet. 1995;345(8955):939–44.
Wolmark N et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993;11(10):1879–87.
O’Connell MJ et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998;16(1):295–300.
Haller DG, Catalano PJ, MacDonald JS, et al. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year final report of INT-0089. Proc Am Soc Clin Oncol. 1998;17:256.
Wolmark N et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999;17(11):3553–9.
Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet. 2000;355(9215):1588–96.
Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol. 1999;17(5):1356–63.
Schrag D, Gelfand S, Bach P, et al. Adjuvant chemotherapy for stage II colon cancer: insight from a SEER-Medicare cohort. Proc Am Soc Clin Oncol. 2001;20:488.
Mamounas E et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol. 1999;17(5):1349–55.
Buyse M, Piedbois P. Should Dukes’ B patients receive adjuvant therapy? A statistical perspective. Semin Oncol. 2001;28(1 Suppl 1):20–4.
Van Cutsem E et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009;27(19):3117–25.
Topham C, Boni C, Navarro M, et al. Multicenter international randomized study of oxaliplatin/5FU/LV (FOLFOX) in stage II and III colon cancer (MOSAIC trial): final results. Eur J Cancer. 2003;1 Suppl 5:S324–5. abstract 1085.
Andre T et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–16.
Andre T et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51.
O’Connell MJ. Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in. J Clin Oncol. 2009;27(19):3082–4.
Allegra CJ et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol. 2009;27(20):3385–90.
Carrato A. Adjuvant treatment of colorectal cancer. Gastrointest Cancer Res. 2008;2(4 Suppl):S42–6.
Krook JE et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324(11):709–15.
Willett C et al. Local failure following curative resection of colonic adenocarcinoma. Int J Radiat Oncol Biol Phys. 1984;10(5):645–51.
Gunderson LL, Sosin H, Levitt S. Extrapelvic colon – areas of failure in a reoperation series: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 1985;11(4):731–41.
Willett CG et al. Postoperative radiation therapy for high-risk colon carcinoma. J Clin Oncol. 1993;11(6):1112–7.
Schild SE et al. The treatment of locally advanced colon cancer. Int J Radiat Oncol Biol Phys. 1997;37(1):51–8.
Amos EH et al. Postoperative radiotherapy for locally advanced colon cancer. Ann Surg Oncol. 1996;3(5):431–6.
Martenson J, Willett C, Sargent D, et al. A phase III study of adjuvant radiation therapy (RT), 5-fluorouracil (5-FU), and levamisole (LEV) vs. 5-FU and LEV in selected patients with resected, high-risk colon cancer: initial results of INT 0130. Proc Am Soc Clin Oncol. 1999;18:235. abstract.
Gunderson LL et al. Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. Int J Radiat Oncol Biol Phys. 2002;54(2):386–96.
Schultz I et al. Longterm results and functional outcome after Ripstein rectopexy. Dis Colon Rectum. 2000;43(1):35–43.
Shibata D et al. Immediate reconstruction of the perineal wound with gracilis muscle flaps following abdominoperineal resection and intraoperative radiation therapy for recurrent carcinoma of the rectum. Ann Surg Oncol. 1999;6(1):33–7.
Paty P et al. Long-term results of local excision for rectal cancer. Ann Surg. 2002;236:522–9.
Russell A et al. Anal sphincter conservation for patients with adenocarcinoma of the distal rectum: long-term results of radiation therapy oncology group protocol 89-02. Int J Radiat Oncol Biol Phys. 2000;46:313–22.
Chakravarti A et al. Long-term follow-up of patients with rectal cancer managed by local excision with and without adjuvant irradiation. Ann Surg. 1999;230:49–54.
Mendenhall W et al. Local excision and postoperative radiation therapy for rectal adenocarcinoma. Int J Cancer. 2001;96:89–96.
Hight D et al. Linear cauterization for the treatment of rectal prolapse in infants and children. Surg Gynecol Obstet. 1982;154:400–2.
Gimbel M, Paty P. A current perspective on local excision of rectal cancer. Clin Colorectal Cancer. 2004;4(1):26–35.
Ota DM, Nelson H. Local excision of rectal cancer revisited: ACOSOG protocol Z6041. Ann Surg Oncol. 2007;14(2):271.
Bullard Dunn K. Adjuvant and neoadjuvant therapy for rectal cancer. Access MedicineUpdate, Schwartz’s principles of surgery. 8th ed. doi: http://www.accessmedicine.com/updatesContent.aspx?aid=1000693.
Heald R, Husband E, Ryall R. The mesorectum in rectal cancer surgery: the clue to pelvic recurrence? Br J Surg. 1982;69:613–6.
Heald R et al. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978–1997. Arch Surg. 1998;133:894–9.
Kapeteijn E et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–46.
Initial report from a Swedish multicentre study examining the role of preoperative irradiation in the treatment of patients with resectable rectal carcinoma. Swedish Rectal Cancer Trial. Br J Surg. 1993;80(10):1333–6.
Camma C et al. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA. 2000;284(8):1008–15.
Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet. 2001;358(9290):1291–304.
Glimelius B et al. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol. 2003;42(5–6):476–92.
Moriya Y et al. Significance of lateral node dissection for advanced rectal carcinoma at or below the peritoneal reflection. Dis Colon Rectum. 1989;32(4):307–15.
Heald RJ, Karanjia ND. Results of radical surgery for rectal cancer. World J Surg. 1992;16(5):848–57.
Enker WE. Potency, cure, and local control in the operative treatment of rectal cancer. Arch Surg. 1992;127(12):1396–401. discussion 1402.
Wibe A et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg. 2002;89(3):327–34.
Dahlberg M, Glimelius B, Pahlman L. Changing strategy for rectal cancer is associated with improved outcome. Br J Surg. 1999;86(3):379–84.
Martling AL et al. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet. 2000;356(9224):93–6.
Swedish Rectal Cancer Register. http://www.SOS.se/mars/kvaflik.htm.
Kapiteijn E et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638–46.
Bosset JF et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114–23.
Collette L et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol. 2007;25(28):4379–86.
Garcia-Aguilar J et al. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum. 2003;46(3):298–304.
Chen E et al. Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation. Int J Radiat Oncol Biol Phys. 1994;30:169–75.
Minsky B et al. Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol. 1992;10(1):79–84.
Minsky B et al. Sphincter preservation with preoperative radiation therapy and coloanal anastomosis. Int J Radiat Oncol Biol Phys. 1995;31:553–9.
Minsky B et al. Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. Int J Radiat Oncol Biol Phys. 1997;37:289–95.
Rouanet P et al. Conservative surgery for low rectal carcinoma after high-dose radiation. Functional and oncologic results. Ann Surg. 1995;221(1):67–73.
Janjan N et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys. 1999;44(5):1027–38.
Kaminsky-Forrett M et al. Prognostic implications of downstaging following preoperative radiation therapy for operable T3–T4 rectal cancer. Int J Radiat Oncol Biol Phys. 1998;42:935–41.
Chan A et al. Preoperative chemotherapy and pelvic radiation for tethered or fixed rectal cancer: a phase II dose escalation study. Int J Radiat Oncol Biol Phys. 2000;48:843–56.
Theodoropoulos G et al. T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum. 2002;45:895–903.
Moore H et al. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum. 2004;47(3):279–86.
Bullard KM et al. Primary perineal wound closure after APR: doomed to fail? Dis Colon Rectum. 2005;48(3):438–443.
Nissan A et al. Abdominoperineal resection for rectal cancer at a specialty center. Dis Colon Rectum. 2001;44(1):27–36.
Luna-Perez P et al. Morbidity and mortality following abdominoperineal resection for low rectal adenocarcinoma. Rev Invest Clin. 2001;53(5):388–95.
Papacontantinou H et al. Salvage APR after failed Nigro protocol: modest success, major morbidity. Dis Colon Rectum. 2003;46(5):A63.
Janjan N et al. Locally advanced rectal cancer: surgical complications after infusional chemotherapy and radiation therapy. Radioology. 1998;206(1):131–6.
Temple L, Wong W, Minsky B. The impact of radiation on functional outcomes in patients with rectal cancer and sphincter preservation. Semin Rad Oncol. 2003;13(4):469–77.
Pahlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial. Ann Surg. 1990;211(2):187–95.
Sauer R et al. Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German rectal cancer trial. Colorectal Dis. 2003;5:406–15.
Sauer R et al. Preoperative versus postoperative chemoradiation for rectal cancer. N Engl J Med. 2004;351(17):1731–40.
Fakih MG et al. Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2008;72(3):650–7.
Rodel C et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol. 2007;25(1):110–7.
Bamberger P, Otchy D. Ileoanal pouch in the active duty population: effect on military career. Dis Colon Rectum. 1997;40(1):60–6.
Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy for resectable rectal cancer. N Engl J Med. 1997;336:980–7.
Habr-Gama A et al. Low rectal cancer: impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum. 1998;41(9):1087–96.
Stein D et al. Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal cancer. Dis Colon Rectum. 2003;46(4):448–53.
Frigell A et al. Quality of life of patients treated with abdominoperineal resection or anterior resection for rectal carcinoma. Ann Chir Gynaecol. 1990;79(1):26–30.
Taal BG, Van Tinteren H, Zoetmulder FA. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer. 2001;85(10):1437–43.
Pahlman L, Glimelius B, Enblad P. Clinical characteristics and their relation to surgical curability in adenocarcinoma of the rectum and rectosigmoid. A population-based study on 279 consecutive patients. Acta Chir Scand. 1985;151(8):685–93.
Moertel CG et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 1969;2(7626):865–7.
Overgaard M, Berthelsen K, Dahlmark M, Gadeberg CG, van der Maase H, Overgaard J, et al. A randomized trial of radiotherapy alone or combined with 5-FU in the treatment of locally advanced colorectal carcinoma. ECCO 5, meeting abstract;1989:0-0626.
Wassif SB. The role of pre-operative adjuvant therapy in the management of borderline operability rectal cancer. Clin Radiol. 1982;33(3):353–8.
Frykholm GJ, Pahlman L, Glimelius B. Combined chemo- and radiotherapy vs. radiotherapy alone in the treatment of primary, nonresectable adenocarcinoma of the rectum. Int J Radiat Oncol Biol Phys. 2001;50(2):427–34.
Janjan NA et al. Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. Radiother Oncol. 1999;51(2):153–60.
Bouzourene H et al. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer. 2002;94(4):1121–30.
Mathis KL et al. Unresectable colorectal cancer can be cured with multimodality therapy. Ann Surg. 2008;248(4):592–8.
Glynne-Jones R, Sebag-Montefiore D. Chemoradiation schedules – what radiotherapy? Eur J Cancer. 2002;38(2):258–69.
Valentini V et al. Preoperative chemoradiation with cisplatin and 5-fluorouracil for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, sphincter preservation. Int J Radiat Oncol Biol Phys. 1999;45(5):1175–84.
Grann A et al. Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer. Dis Colon Rectum. 1997;40(5):515–22.
Hyams DM et al. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03. Dis Colon Rectum. 1997;40(2):131–9.
Rouanet P et al. Restorative and nonrestorative surgery for low rectal cancer after high-dose radiation: long-term oncologic and functional results. Dis Colon Rectum. 2002;45(3):305–13. discussion 313–5.
Mohiuddin M et al. High-dose preoperative radiation and the challenge of sphincter-preservation surgery for cancer of the distal 2 cm of the rectum. Int J Radiat Oncol Biol Phys. 1998;40(3):569–74.
Moore HG et al. Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined-modality therapy. Ann Surg Oncol. 2003;10(1):80–5.
Karnjia ND, Schache DJ, North WR, Heald RJ. “Close shave” in anterior resection. Br J Surg. 1990;63:673–7.
Francois Y et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol. 1999;17(8):2396.
Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol. 2004;72:15–24.
Hanna Jr MG et al. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine. 2001;19(17–19):2576.
Hoover Jr HC et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol. 1993;11(3):390–9.
Harris JE et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol. 2000;18(1):148–57.
Vermorken JB et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet. 1999;353(9150):345–50.
Fallik D et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res. 2003;63(18):5738–44.
Barratt PL et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet. 2002;360(9343):1381–91.
Des Guetz G et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer. 2009;45(10):1890–6.
Gusella M et al. Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br J Cancer. 2009;100(10):1549–57.
Afzal S et al. MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Ann Oncol. 2009;20(10):1660–6.
Khambata-Ford S et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25(22):3230–7.
Freeman DJ et al. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer. 2008;7(3):184–90.
Amado RG et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626–34.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 ASCRS (American Society of Colon and Rectal Surgeons)
About this chapter
Cite this chapter
Dunn, K.B., Trudel, J.L. (2011). Colorectal Cancer: Adjuvant Therapy. In: Beck, D.E., Roberts, P.L., Saclarides, T.J., Senagore, A.J., Stamos, M.J., Wexner, S.D. (eds) The ASCRS Textbook of Colon and Rectal Surgery. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1584-9_46
Download citation
DOI: https://doi.org/10.1007/978-1-4419-1584-9_46
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-1581-8
Online ISBN: 978-1-4419-1584-9
eBook Packages: MedicineMedicine (R0)